Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The reticuloendothelial system (RES) phagocytic cells in sentinel lymph nodes, primarily macrophages and dendritic cells, serve as the functional targets for diagnostic imaging agents used in sentinel lymph node (SLN) mapping (StatPearls, NBK441863). These cells are concentrated in the subcapsular and medullary sinuses of the lymph nodes, where they perform vital immune surveillance by clearing debris and pathogens from the lymphatic fluid (PubMed, 15927471). In clinical practice, the identification of the SLN—the first node receiving drainage from a tumor—is crucial for accurate cancer staging and surgical planning. Agents such as Technetium Tc 99m tilmanocept are designed to bind with high affinity to the mannose receptor (CD206) residing on the surface of these phagocytic cells (FDA, Lymphoseek Label). Other agents, like sulfur colloids, rely on the innate phagocytic activity of these cells for localization (StatPearls, NBK441863). By targeting these specific cell populations, clinicians can visualize the lymphatic pathway and assess the risk of metastatic spread in diseases like breast cancer and melanoma (Journal of Nuclear Medicine, 2013). While not a single molecular target, this cell population is essential for the efficacy of lymphoscintigraphy and radioguided surgery. The mannose receptor (CD206) is the primary molecular marker exploited for specific targeting in this context. Safety concerns for agents targeting these cells include hypersensitivity and minor radiation exposure. Overall, these phagocytic cells are pivotal for diagnostic precision in oncology.
Diagnostic agents target these cells through receptor-mediated binding to the mannose receptor (CD206) or via non-specific phagocytosis of colloidal particles, allowing for the visualization of lymphatic drainage patterns.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reticuloendothelial system phagocytic cells in sentinel lymph nodes (RES phagocytic cells (SLN)).